Year-end Sale % OFF 
Abstract
To compare overall survival (OS) and disease-free survival (DFS) following percutaneous alcohol injection (PEI) and radiofrequency ablation (RFA) for the treatment of hepatocellular carcinoma. This is a single-institution retrospective cohort study. Patients who underwent PEI or RFA between 2005 and 2009 for hepatocellular carcinoma without extrahepatic metastases were included in this analysis. Patient data was collected between the time of procedure to September 1, 2017. A chart review was performed for baseline characteristics, clinical success, complications, survival, disease recurrence, additional treatment, and transplant. Statistical analysis was performed using SPSS (IBM, New York). 126 patients are included in this analysis. 56 patients were treated with PEI and 70 patients with RFA. The RFA group had a significantly higher proportion of patients with Child Pugh A liver cirrhosis and tumors <3 cm. Technical success was 95% and 98% for PEI and RFA, respectively. Complication rates for PEI and RFA were 11% and 9%, respectively. OS and DFS are summarized in Table 1. Patients in the RFA group had significantly higher OS at 2, 3, 4, and 5 years. Between 6 and 9 years there was no significant difference in OS between the two groups. Differences in DFS between PEI and RFA at all time points did not reach statistical significance. Analysis limited to patients with tumors <3 cm demonstrated significantly higher OS in patients treated with RFA only at 1 and 5 years. The remaining time points showed no significant difference between the two groups. Similarly, analysis limited to patients with Child Pugh A liver cirrhosis showed significantly higher OS in the RFA group only at 3 and 4 years. PEI and RFA have comparable DFS and long-term OS in patients with small hepatomas and good liver status based on Child-Pugh score.Table 1YearPEI OS (%)RFA OS (%)PPEI DFS (%)RFA DFS (%)P179870.352570.5245710.0129410.2335560.0129290.6431530.0123270.3523430.0121230.4623360.0721200.5723340.121200.6823310.221170.8920280.120160.7 Open table in a new tab
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
